Gene Therapy Crisis? Sarepta Therapeutics Faces Backlash Over Elevidys Deaths and Disclosure Timing
Sarepta Therapeutics (NASDAQ: SRPT) is under intense scrutiny after reports emerged linking its gene therapy treatment, Elevidys, to multiple patient deaths. The biotech company, known for its pioneering work in treating Duchenne muscular dystrophy (DMD), is now facing mounting pressure from investors, regulators, and the medical community over how it handled the crisis and its communications timeline.
At the heart of the controversy is Elevidys, Sarepta’s high-profile gene therapy for DMD that received accelerated FDA approval in 2023 for ambulatory patients aged 4 through 5. The therapy had been hailed as a breakthrough, offering a potentially life-changing option for children suffering from this rare, degenerative muscle disorder. However, recent reports suggest that several patients died while undergoing the treatment, sparking questions about the therapy’s safety profile.
What has rattled the market even more is the allegation that Sarepta may have delayed disclosing the deaths to the public and investors. According to regulatory filings and sources familiar with the matter, some of the fatalities occurred as early as the first quarter of the year, yet details were only made public in a recent SEC filing. This delay has prompted concerns over corporate transparency and the ethical obligations of biotech firms working with vulnerable populations.
Shares of SRPT have been volatile in recent days, reflecting the uncertainty surrounding the FDA’s next steps. The agency is reportedly evaluating the adverse event reports and could take regulatory action, including narrowing Elevidys’ label, placing clinical holds on ongoing trials, or in the worst-case scenario, revoking the therapy’s approval altogether.
The biotech community is watching closely, with some suggesting that Sarepta may become a takeover target in the wake of its weakened market position. Despite the crisis, the company still holds a promising pipeline beyond Elevidys, including follow-up gene therapies and RNA-based treatments. The valuation has dropped significantly since the beginning of July, making SRPT potentially attractive to larger pharmaceutical companies seeking to expand in the rare disease or gene therapy sectors.
CEO Doug Ingram is facing sharp criticism for not addressing the deaths earlier and for downplaying the severity of the events in public remarks. Several analysts have downgraded the stock, warning that trust has been eroded and recovery will depend on both the FDA’s verdict and the company’s transparency moving forward.
Investors are now weighing high-risk, high-reward scenarios. On one hand, the company could rebound if the FDA maintains its approval and new safety protocols restore confidence. On the other hand, the fallout from a loss of approval or deeper investigations could have lasting reputational and financial consequences.
Sarepta Therapeutics, headquartered in Cambridge, Massachusetts, operates in the biotechnology sector and trades on the NASDAQ under the ticker SRPT. Its current predicament serves as a harsh reminder of the risks inherent in cutting-edge gene therapies and the paramount importance of timely, transparent communication in public health.